MedTrace Logo

Clinical Effect of Rebamipide on Chronic Gastritis

NCT02393430 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2015-03-19

No results posted yet for this study

Summary

To investigate the clinical effect of rebamipide in chronic gastritis patients. Patients with chronic gastritis were randomly divided into the experimental group and the control group. The experimental group were treated with rebamipide 0.1g tid and optimization of life style, and the control group were only optimized their life style for 26 weeks. Upper gastrointestinal endoscopy was performed in all patients to evaluate the severity of gastritis by modified Lanza score (MLS) and the histology by the updated Sydney system before and after treatment.

Conditions

  • Gastritis

Interventions

DRUG

Rebamipide

Rebamipide is a

BEHAVIORAL

optimization of life style

Sponsors & Collaborators

  • BangMao Wang

    lead OTHER

Principal Investigators

  • Wang Bang-mao · Tianjin meidcal university general hospital,China

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-05-31
Primary Completion
2014-06-30
Completion
2014-06-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02393430 on ClinicalTrials.gov